An interventional study of Native PATHS in Alcohol Drinking, Tobacco Use and Drug Use, sponsored by University of Rhode Island. Recruiting at 1 site in United States. Open to participants aged 10 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.
Sponsored by University of Rhode Island · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.
Among the 313 studies in Tobacco Use with a site in United States, this one is the 195th largest by planned enrollment of the 288 interventional ones that give a count, is one of 22 that started in 2024, is one of 233 with no phase, reaches primary completion later than 2 of the 64 other live ones, and was the 216th registered.
423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.
Browse Tobacco Use studies →54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.
This study: 10 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 22 · Phase 3 10 · Phase 4 9
First in 1992; this study’s year is marked. 22 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 131 across 354 interventional studies indexed under Tobacco Use.
Median enrollment 120 across the 288 interventional studies, 174 across the 24 observational. Of the 232 that completed or were terminated, 82 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 313 have an industry lead sponsor. The 10 most frequent:
University of Rhode Island is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
University of Rhode Island has 1 study filed under Tobacco Use — fewer than ten, so there is no comparison to draw.
33 of the studies in Tobacco Use with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05707871Wake Forest University Health SciencesCardiovascular Effects of Very Low Nicotine Content Cigarettes | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT05445804Johns Hopkins UniversityOral Cannabidiol for Tobacco Cessation | 2026-12-01 |
| NCT07598136RAI Services CompanyA Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers | 2026-12-17 |
| NCT04297592Mayo ClinicAntibiotic Prophylaxis in High-Risk Arthroplasty Patients | 2027-01 |
Add all 33 to your calendar (.ics) → With an account.
Among the 313 studies in Tobacco Use with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this project is to develop and obtain preliminary data on acceptability, feasibility, and initial efficacy of Native PATHS. This work is guided by the stage model guidelines for treatment development and adaptation 25. Stage 1a will occur in two sequential steps. First, the investigators will recruit youth who are in 5th - 8th grade and their family members (N=24, 12 youth, 12 adults 18+) to participate in three talking circle sessions to obtain feedback on the cultural adaptation and implementation of the treatment. Next, the investigators will conduct an open label pilot (N=9). Youth and their family members, (up to 3 per youth) will provide qualitative and quantitative feedback after each session. In Stage 1b, 60 youth will participate in a pilot randomized controlled trial, testing the efficacy of the newly created program (n=30) against a wait list control (WLC) condition (n=30). Ultimately, this program of research is expected to result in a well-specified, efficacious prevention program that could be readily disseminated and generalizable to other Indigenous populations with minimal adaptation.
Alcohol is one of the primary determinants of health disparity among many Indigenous populations with rates of alcohol-attributable mortality substantially higher than for Whites (73.8 per 100,000 vs. 27.5), and therefore, is a key threat to optimal health and well-being to Indigenous youth. Indigenous youth living in both the US and Canada tend to begin using alcohol, tobacco, and other drugs (ATOD) at earlier ages than most other ethnic/racial groups, and tend to move more quickly to regular use, resulting in earlier onset of ATOD disorders. Despite the severity of the problem, there continues to be an urgent unmet need for effective prevention programs that are culturally tailored to Indigenous populations of the US and Canada. The overall objective of this project is to develop and obtain preliminary data on the acceptability, feasibility, and initial efficacy of Native PATHS (Positive Approaches to reducing Harm from Substance Use). Native PATHS is a strengths-based, family prevention program for Indigenous youth in 5th-8th grade which focuses on delayed ATOD initiation. The development of Native PATHS has been guided by formative work in this community, taking a behavioral economic and positive psychological approach to prevention. Applied to prevention, behavioral economic theory focuses on reducing the availability of ATOD and increasing ATOD-free alternatives and the reinforcement received from engaging in ATOD-free activities. Activities in Native PATHS will work with families to help with establishing ATOD-free rules, limit physical availability of ATOD in the home, and reinforce youths' participation in ATOD-free activities. Positive psychological interventions (PPIs) focus on increasing positive emotions, life satisfaction, and well-being. PPIs will be used to enhance the enjoyment received from ATOD-free activities and to improve life satisfaction. Native PATHS is culturally consistent with North American Indigenous views of health that describe health in terms of a balance between the physical, spiritual, emotional, and mental aspects of life, which is represented in the teachings of the Medicine Wheel. Collaboratively, the investigators will work together with tribal partners on further adaptation of the program to include family and Indigenous ways of parenting in a culturally meaningful way. The overall goals proposed project will 1) finalize Native PATHS with participation from youth and family members in talking circles and an open pilot trial; 2) assess the effectiveness of Native PATHS in reducing ATOD initiation and intentions to use ATOD; 3) begin to evaluate the possible mechanisms/moderators of action including potential mediators future orientation and alternative reinforcer/activity engagement and reinforcement received, compared to a wait-list control group. The investigators will also evaluate positive affect as a potential moderator of any treatment effect, such that those higher in positive affect will be less likely to engage in ATOD use and be less likely to endorse intentions to use ATOD.
423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.
This study's planned enrollment of 60 is below the median of 131 across 354 interventional studies indexed under Tobacco Use.
Browse Tobacco Use studies →University of Rhode Island is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
Compared within Tobacco Use, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria - Youth Participants:
Inclusion Criteria - Family Participants:
A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
Behavioral: Native PATHS
Participants will receive the Native PATHS program once 6-month follow up surveys have been completed.
A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
Past month alcohol use
Respondents will be asked whether they have used alcohol in the past month (yes/no).
Time frame: Baseline
Past month alcohol use
Respondents will be asked whether they have used alcohol in the past month (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past month alcohol use
Respondents will be asked whether they have used alcohol in the past month (yes/no).
Time frame: Six months following end of treatment
Past three-month alcohol use
Respondents will be asked whether they have used alcohol in the past three months (yes/no).
Time frame: Baseline
Past three-month alcohol use
Respondents will be asked whether they have used alcohol in the past three months (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past three-month alcohol use
Respondents will be asked whether they have used alcohol in the past three months (yes/no).
Time frame: Six months following end of treatment
Past month marijuana use
Respondents will be asked whether they have used marijuana in the past month (yes/no).
Time frame: Baseline
Past month marijuana use
Respondents will be asked whether they have used marijuana in the past month (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past month marijuana use
Respondents will be asked whether they have used marijuana in the past month (yes/no).
Time frame: Six months following end of treatment
Past three-month marijuana use
Respondents will be asked whether they have used marijuana in the past three months (yes/no).
Time frame: Baseline
Past three-month marijuana use
Respondents will be asked whether they have used marijuana in the past three months (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past three-month marijuana use
Respondents will be asked whether they have used marijuana in the past three months (yes/no).
Time frame: Six months following end of treatment
Past month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).
Time frame: Baseline
Past month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).
Time frame: Six months following end of treatment
Past three-month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).
Time frame: Baseline
Past three-month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).
Time frame: End of treatment (up to 12 weeks following baseline)
Past three-month cigarette smoking
Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).
Time frame: Six months following end of treatment
Alcohol use intentions
Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.
Time frame: Baseline
Alcohol use intentions
Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.
Time frame: End of treatment (up to 12 weeks following baseline)
Alcohol use intentions
Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.
Time frame: Six months following end of treatment
Cigarette smoking susceptibility
Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.
Time frame: Baseline
Cigarette smoking susceptibility
Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.
Time frame: End of treatment (up to 12 weeks following baseline)
Cigarette smoking susceptibility
Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.
Time frame: Six months following end of treatment
Marijuana use intentions
Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.
Time frame: Baseline
Marijuana use intentions
Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.
Time frame: End of treatment (up to 12 weeks following baseline)
Marijuana use intentions
Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.
Time frame: Six months following end of treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for May 2025, 11 months later.
Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Rhode Island